menu

Indolent Systemic Mastocytosis (ISM): Tools to Diagnose ISM

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Indolent Systemic Mastocytosis (ISM): Tools to Diagnose ISM

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Cem Akin, MD
    Clinical Professor
    Allergy and Immunology, Internal Medicine
    University of Michigan Health
    Ann Arbor, MI

    Consultanting Fees: Aquestive, Blueprint Medicines Corporation, Celldex, Cogent, Novartis
    Research Grant: Blueprint Medicines Corporation

    Faculty:
    Jason Gotlib, MD, MS
    Associate Professor of Medicine, Stanford Cancer Institute
    Stanford Medicine
    Palo Alto, CA

    Consulting Fees or Advisory Role: AbbVie, Blueprint Medicines Corporation, BMS, Celgene, Cogent Biosciences, Deciphera, Incyte, Kartos, Therapeutics, Novartis, PharmaEssentia, Protagonist Therapeutics
    Research Funding: Blueprint Medicines Corporation, Celgene, CTI BioPharma Corp, Deciphera, Gilead Sciences, Incyte, Kartos, Novartis, Promedior, Seattle Genetics, Therapeutics
    Honoraria: AbbVie, Blueprint Medicines Corporation, BMS, Celgene, Cogent Biosciences, Deciphera, Incyte, Kartos, Novartis, PharmaEssentia, Protagonist Therapeutics

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Libby Lurwick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss various signs and symptoms associated with indolent systemic mastocytosis (ISM)
    • Understand the need for a thorough examination of each patient’s medical history, including prior physician and emergency department visits
    • Identify updates in the diagnostic criteria of ISM, including what differentiates it from other forms of mastocytosis
  • Target Audience

    This activity is designed to meet the educational needs of hematologist oncologists, allergists and allergy immunologists, emergency medicine physicians, gastroenterologists, dermatologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Podcast | PLUS activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Cem Akin, MD
    Clinical Professor
    Allergy and Immunology, Internal Medicine
    University of Michigan Health
    Ann Arbor, MI

    Consultanting Fees: Aquestive, Blueprint Medicines Corporation, Celldex, Cogent, Novartis
    Research Grant: Blueprint Medicines Corporation

    Faculty:
    Jason Gotlib, MD, MS
    Associate Professor of Medicine, Stanford Cancer Institute
    Stanford Medicine
    Palo Alto, CA

    Consulting Fees or Advisory Role: AbbVie, Blueprint Medicines Corporation, BMS, Celgene, Cogent Biosciences, Deciphera, Incyte, Kartos, Therapeutics, Novartis, PharmaEssentia, Protagonist Therapeutics
    Research Funding: Blueprint Medicines Corporation, Celgene, CTI BioPharma Corp, Deciphera, Gilead Sciences, Incyte, Kartos, Novartis, Promedior, Seattle Genetics, Therapeutics
    Honoraria: AbbVie, Blueprint Medicines Corporation, BMS, Celgene, Cogent Biosciences, Deciphera, Incyte, Kartos, Novartis, PharmaEssentia, Protagonist Therapeutics

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Libby Lurwick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss various signs and symptoms associated with indolent systemic mastocytosis (ISM)
    • Understand the need for a thorough examination of each patient’s medical history, including prior physician and emergency department visits
    • Identify updates in the diagnostic criteria of ISM, including what differentiates it from other forms of mastocytosis
  • Target Audience

    This activity is designed to meet the educational needs of hematologist oncologists, allergists and allergy immunologists, emergency medicine physicians, gastroenterologists, dermatologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Podcast | PLUS activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Sep 2022
Webpack App